Monitor for use of proceeds toward pipeline catalysts (revumenib, entinostat) and any subsequent equity issuances that could accelerate dilution. The convertible structure provides a low-cost financing source (2.25% coupon) but creates overhang given the conversion premium. Watch for any fundamental change events that could trigger note repurchase rights.
SNDX drugs
SNDX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $17.91entry
- T+1 · 5mo ago +1.90%α +1.36% · $18.25
- T+5 · 5mo ago +6.31%α +5.88% · $19.04
- T+20 · 4mo ago +38.69%α +36.80% · $24.84
- T+60 · 2mo ago +14.80%α +10.40% · $20.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Syndax Pharmaceuticals issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, generating net proceeds of approximately $243 million. The company plans to use the funds for general corporate purposes including R&D, commercialization, and business development. The notes are convertible into common stock at an initial rate of 40.3894 shares per $1,000 principal, with a maximum potential dilution of up to 13,631,400 shares.
Key Financial Metrics
Key Facts
- Issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
- Net proceeds of approximately $243 million after fees and expenses
- Initial conversion rate of 40.3894 shares per $1,000 principal amount of Notes
- Maximum of 13,631,400 shares of common stock may be issued upon conversion
- Notes mature on June 15, 2031
- Interest payable semi-annually at 2.25% per year
- Notes are not redeemable by the company prior to June 20, 2029
- Proceeds to be used for general corporate purposes including R&D, commercialization, and business development
Financial Impact
$250 million convertible note issuance with $243 million net proceeds; potential dilution of up to 13.6 million shares (approximately 8-10% of current shares outstanding based on $1.6B market cap)
Risk Factors
- Potential dilution of up to 13.6 million shares upon conversion
- Interest expense of ~$5.6 million annually on the notes
- Conversion may be accelerated if stock price trades above 130% of conversion price for 20 of 30 consecutive trading days
- Fundamental change events could trigger mandatory repurchase at 100% of principal plus accrued interest
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-266027 |
| Document: d105044dex42.htm | 0001193125-26-266027 |
| Document: d105044d8k.htm | 0001193125-26-266027 |
| Document: 0001193125-26-266027-index-headers.html | 0001193125-26-266027 |
| Document: 0001193125-26-266027-index.html | 0001193125-26-266027 |
| Document: 0001193125-26-266027.txt | 0001193125-26-266027 |
Track record
16 reports on SNDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 2/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
- Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
- Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers